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In vitro anti-genotoxic properties of bile pigments have been explored and conﬁrmed recently. Despite
these reports mechanisms to explain DNA protection by endogenous bile pigments remain unclear. Sur-
prisingly, the quantiﬁcation of cellular pigment absorption which could represent a fundamental prere-
quisite for intracellular (e.g., anti-mutagenic) effects, has not been explored. Therefore, we aimed to
measure the amounts of un-/conjugated bilirubin as well as biliverdin absorbed into colonies of Salmo-
nella typhimurium, utilising HPLC analyses, and to observe whether intracellular compound concentra-
tions could predict anti-genotoxic effects. HPLC analyses conﬁrmed that bacterial bile pigment
absorption was concentration-dependent. Plate bile pigment concentrations were inversely associated
with genotoxicity of all tested mutagens, irrespective of strain and test conditions. However, protection
against frame-shift mutation in strain TA98 most strongly depended on the bacterial absorption of bili-
rubin and biliverdin, which indicates that bile pigments can protect by intercepting mutations extracel-
lularly and speciﬁcally inhibit frame-shift mutations intracellularly.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Bile pigments (BPs) such as bilirubin (BR) and biliverdin (BV)
are tetrapyrrolic, dicarboxylic compounds derived from the enzy-
matic heme degradation. They are distributed throughout the body
and thus could play an essential role in systemic and tissue-speciﬁc
health promotion. Numerous studies have identiﬁed anti-
mutagenic and anti-oxidative activity of speciﬁc tetrapyrroles
(TPs) in vitro (Asad et al., 2001; Bulmer et al., 2007). In vivo data
also demonstrate disease prevention through vasoprotection,
inhibition of inﬂammation and anti-oxidant activity (Bulmer
et al., 2008b; McCarty, 2007). Multiple underlying mechanisms of
anti-genotoxic action have been hypothesised but remain to be
conﬁrmed. Surprisingly, no publication has focused on quantifying
cellular BP absorption which could form a fundamental basis for
intracellular action. Therefore, we aimed to quantify the absorption
of BR, BV and conjugated BR (ditaurate; BRDT) into two distinctgment(s); BR, unconjugated
PhIP, 2-amino-1-methyl-6-
ella, Salmonella typhimurium;
trinitro-9H-ﬂuoren-9-one.
nna, Faculty of Life Sciences,
thanstraße 14, 1090 Vienna,
9.
Mölzer).
Y-NC-ND license.strains of Salmonella typhimurium (S. typhimurium) via HPLC analy-
ses. It was hypothesised that BPs would be absorbed in a dose-
dependent manner into bacteria, and that extracellular (plate)
and intracellular (absorbed) BP concentrations would broadly
protect against genotoxicity mediated by various mutagens.2. Materials and methods
2.1. Salmonella reverse mutation assay
The Salmonella reverse mutation assay is an in vitro test assess-
ing the mutagenic potential of chemicals. Bacterial wild-type
reversion in the presence of mutagens, allowing growth and colony
formation represents its fundamental, technical basis. Experiments
were conducted as previously published (Maron and Ames, 1983),
and included 48 h of BP incubation at 37 C. In some assays, S9 liver
homogenate (S9 microsomal fraction from Aroclor-treated rats)
was used as an enzymatic activation system. Bile pigment concen-
trations were tested in triplicate, negative/positive controls were
tested in each assay (n = 6). Experiments were repeated again on
a different day and results were then pooled (n = 6 minimum).
2.1.1. Bacterial strains
Two strains of S. typhimuriumwere tested: TA102, susceptible to
oxidative damage, reverts by cross-linking agents, TA98 detects
Table 1
Correlations between BP plate concentrations and bacterial pigment absorption in
Salmonella strains TA98 and TA102 (‘‘availability-based absorption’’).
Compound Strain Mutagen conc.
[mol/plate]
S9 Correlation (r)
BP absorption  BP plate
conc.
BR TA98 TNFone, 0.3  106  0.693**
BR TA102 TNFone, 0.2  107  0.972**
BR TA98 PhIP, 0.1  107 + 0.687**
BR TA98 AfB1, 0.8  107 + 0.982**
BR TA102 t-BOOH, 0.75  106  0.691**
BV TA98 PhIP, 0.1  107 + 0.949**
BV TA98 AfB1, 0.8  107 + 0.972**
BV TA102 AfB1, 0.24  106 + 0.949**
BV TA102 t-BOOH, 0.75  106  0.949**
BV TA102 t-BOOH, 0.75  106 + 0.949**
BRDT TA98 PhIP, 0.1  107 + 0.885**
BRDT TA102 AfB1, 0.24  106 + 0.972**
BRDT TA102 t-BOOH, 0.75  106  0.878*
BRDT TA102 t-BOOH, 0.75  106 + 0.814**
S9: metabolic activation system (microsomal fraction from Aroclor-treated rats);
BP: bile pigment; BR: unconjugated bilirubin; BV: biliverdin; BRDT: bilirubin
ditaurate; TNFone: 2,4,7-trinitro-9H-ﬂuoren-9-one; PhIP: 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine; AfB1: aﬂatoxin B1; t-BOOH: tertiary butyl
hydroperoxide.
** Signiﬁcant on p 6 0.01.
* Signiﬁcant on p 6 0.05.
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Zeiger, 2000). Strains were kindly provided by Dr. Bruce N. Ames
and were attested to their genetic integrity and spontaneous
mutation rate (Mortelmans and Zeiger, 2000) in our laboratory.2.1.2. Chemicals
Unconjugated bilirubin 1Xa (CAS# 635-65-4), conjugated bili-
rubin (ditaurate; CAS# 635-65-4) and biliverdin 1Xa (CAS#
55482-27-4) were purchased from Frontier Scientiﬁc Europe, UK.
Chemical structures can be found online (Supplementary material
1). Pigment purity (>98%) and solubility were measured using
HPLC and spectrophotometry. The S9 liver homogenate was ob-
tained from MP Biomedicals, France. All other reagents and muta-
gens were purchased from Sigma Aldrich, Austria (unless
otherwise noted), were of the highest analytical grade available,
and stored according to instructions. Bile pigment solutions were
prepared in DMSO, protected from light, and used immediately.
Composition and preparation of all necessary solutions can be
found elsewhere (Bulmer et al., 2007). To assess different possibil-
ities of anti-genotoxic action (e.g., structural interactions, radical
scavenging, complex formation), four different mutagens wereTable 2
Correlations between BP plate concentrations or bacterial BP absorption, respectively, and
mutagenic effects’’ and ‘‘absorption-based anti-mutagenic effects’’).
Compound Strain Mutagen conc. [mol/plate] S9 Correlation (r) BP pla
BR TA98 TNFone, 0.3  106  0.794**
BR TA102 TNFone, 0.2  107  0.682**
BV TA102 TNFone, 0.2  107  0.493**
BV TA98 PhIP, 0.1  107 + 0.927**
BV TA98 AfB1, 0.8  107 + 0.473**
BV TA102 AfB1, 0.24  106 + 0.601**
BV TA102 t-BOOH, 0.75  106  0.607**
BRDT TA98 TNFone, 0.3  106  0.475**
BRDT TA102 TNFone, 0.2  107  0.378*
BRDT TA98 AfB1, 0.8  107 + 0.548**
BRDT TA102 t-BOOH, 0.75  106  0.754**
S9: metabolic activation system (microsomal fraction from Aroclor-treated rats); BP: b
TNFone: 2,4,7-trinitro-9H-ﬂuoren-9-one; PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-
** Signiﬁcant on p 6 0.01.
* Signiﬁcant on p 6 0.05.applied at their respective appropriate concentrations (Table 1):
2,4,7-trinitro-9H-ﬂuoren-9-one (J & K Ltd., China; TNFone), ter-
tiary-butyl hydroperoxide (Merck; t-BOOH), aﬂatoxin B1 (AfB1)
and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (Toronto
Research Chemicals, Canada; PhIP).
2.1.3. Bile pigment sample preparation for the Salmonella reverse
mutation assay
Based on preceding investigations (Bulmer et al., 2007), BRDT
and BV were tested at concentrations of 0.01, 0.05, 0.1, 0.5, 1 and
2 lmol/plate (equals 3.4, 17.2, 34.5, 172.4, 349 and 689.6 lM).
Unconjugated BR was tested over a range of ﬁve doses including:
0.01, 0.05, 0.1, 0.5 and 0.75 lmol/plate (equals 258.6 lM). Maxi-
mum BP plate concentrations had been ascertained by (1) testing
themaximumamount of DMSO that did not result in bacterial cyto-
toxicity (200 ll/plate) and (2) by the respectivemaximumsolubility
of each test compound (spectrophotometric supernatant analysis:
BR, BRDT: 455 nm; BV: 380 nm), read on a Perkin Elmer Lambda 2
UV/VIS spectrophotometer after high-speed centrifugation.
2.2. Sample preparation for HPLC analyses
Brieﬂy, S. typhimurium colonies (P1 mm in diameter) were
collected from agar plates, and were lysed for 30 min in 40 ll of
isocratic mobile phase (950 ml HPLC-grade methanol, 50 ml
HPLC-grade water, 24.2 g n-dioctylamine and 6.01 g glacial acetic
acid per litre). Supernatants were diluted at 1:4, and injected
(50 ll) into a Hitachi HPLC, equipped with a Shimadzu SPD-
M20A detector, and a C18 reverse phase column (5micron,
250  4.6 m) (Brower et al., 2001; Bulmer et al., 2008b). Oven tem-
perature was set at 35 C, column pressure at 140 bar. Sixteen BP
standards were run, ranging from 500 to 0.01 lM. The method’s
detection limit (LOD) was calculated at 18 nM. Photographs of bac-
terial colonies can be found online (Supplementary material 2).
2.3. Measurement of total protein content
As a reference parameter for bacterial BP absorption, the total
protein content in each diluted sample was measured photometri-
cally (Bradford, 1976). Bile pigment concentrations were then ex-
pressed as nmol/mg total protein.
2.4. Statistical analyses
Data were analysed using SPSS 17.0. A p-value 60.05 was con-
sidered signiﬁcant. Data were tested for normal distribution usinganti-mutagenic effects in Salmonella strains TA98 and TA102 (‘‘availability-based anti-
te conc. x anti-mut. effects Correlation (r) BP absorption x anti-mut. effects
0.938**
0.639**
0.124
0.917**
0.827**
0.216
0.570
0.198
0.203
0.665
0.481
ile pigment; BR: unconjugated bilirubin; BV: biliverdin; BRDT: bilirubin ditaurate;
b]pyridine; AfB1: aﬂatoxin B1; t-BOOH: tertiary butyl hydroperoxide.
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(one-way ANOVA) and the post hoc Scheffé test were performed
on normally distributed, and corresponding non-parametric tests
(Kruskal–Wallis H-test, Dunn’s post hoc test) on skewed data.Fig. 1. (A–C) Relationship between bacterial BP absorption and observed anti-mutagen
strain TA102 with TNFone, (C) BV in strain TA98 with PhIP and with S9.Relationships between (1) BP bacterial absorption and plate
concentrations; (2) BP bacterial absorption and anti-genotoxic
effects; and (3) between BP plate concentrations and anti-
mutagenicity were determined by performing bivariateic effects against different mutagens; (A) BR in strain TA98 with TNFone, (B) BR in
436 C. Mölzer et al. / Toxicology in Vitro 27 (2013) 433–437correlations (Pearson or Spearman for parametric and non-
parametric data, respectively).
3. Results
HPLC analyses showed signiﬁcant concentration-dependent BP
absorption from agar plates, which was independent of strain, test
condition (± S9) and the applied mutagen (Table 1). Furthermore,
anti-mutagenic effects of all BPs against all tested mutagens were
observed (Table 2).
The relationships between BP plate concentrations, bacterial BP
absorption and observed anti-mutagenic effects are shown in
Fig. 1A–C and in Supplementary material 3. Signiﬁcant inverse
relationships were found between BR plate concentrations in
strains TA98 and TA102 and anti-mutagenic action against TNFone,
as well as between BV plate concentration and PhIP mutagenesis in
TA98 (Fig. 1A–C). A typical chromatogram showing BR absorption
into strain TA98 is shown in Fig. 2. Furthermore, signiﬁcant corre-
lations between pigment plate concentrations and anti-genotoxi-
city were found for all test conditions (Table 2), indicating a
stronger concentration-dependent anti-mutagenic effect based on
extracellular (vs. intracellular) BP concentration. Interestingly,
the anti-mutagenic effects of BR and BV were most strongly depen-
dent on the bacterial BP absorption exclusively in strain TA98
(Table 2).
An entirely novel observation was also made in that the ob-
tained HPLC spectra (not shown) suggest appearance of BR in plates
supplemented with BV, which could imply biliverdin reductase
activity in S. typhimurium. The ratio of BV to BR (BV:BR) bacterial
concentrations calculated from HPLC chromatograms (at 1 lmol/
plate BV) approximated 4.4:1 in TA98 and 9.6:1 in TA102.
4. Discussion
This study is the ﬁrst to report on bacterial BP absorption and its
relationship with observed anti-mutagenic effects. When exposed
to mutagens, extracellular (plate) BP concentrations negatively
correlated with genotoxicity. Furthermore, testing in TA98 revealed
that BV and BR absorption was more strongly related with anti-
mutagenesis, when compared to the anti-mutagenic effect relative
to plate concentrations.Fig. 2. Chromatogram of BR (with TNFone) in Salmonella TA98 colonies.Previous reports refer to the ability of BPs to act in an anti-oxi-
dant and anti-genotoxic manner in vitro (Asad et al., 2001; Bulmer
et al., 2007) and in vivo (Boon et al., 2012; Horsfall et al., 2011).
Vastly unclear to date however, are the underlying mechanisms
of anti-genoxic action. In this context mainly electron scavenging
or hydrogen donating capacities (MacLean et al., 2008) and struc-
tural interactions between BPs and mutagens (Hayatsu, 1995) are
discussed. However, data on cellular compound absorption are
lacking and so far only one recent report on enzymatic BRDT reduc-
tion in bacteria (Konickova et al., 2012) exists. Therefore, we ex-
plored whether bacterial BP absorption was more closely related
to anti-mutagenesis compared to extracellular BP concentrations
around S. typhimurium experiencing genotoxic stress.
In this study, physiologically relevant concentrations of BPs
were tested. Un-/conjugated BR is found in the blood, the liver,
the intestine (where about 70% are recycled via the enterohepatic
cycle), and the urinary tract. In these compartments BR is further
metabolised, recycled and/or excreted (Klatskin, 1961). The liver
and gut, which are sites of BP accumulation, are at particular risk
of genotoxicity due to the absorption, metabolism (Guengerich,
2000; Turesky et al., 2002) and excretion of mutagens. The
abundance of BPs within these organs suggests BPs could exert
physiological protection against DNA damage speciﬁcally at these
sites.
Interestingly, BR and BV absorption strongly protected against
frame-shift mutation in the TA98 strain. This mutation represents
an important mechanism of pathogenesis in gastric and colorectal
cancers (Kim et al., 2010). We speculate that the afﬁnity of BPs to
protect against frame-shift mutation, might partly explain the pro-
tective relationship between serum BR levels and colorectal cancer
in vivo (Zucker et al., 2004). It should be emphasised, however, that
BPs do protect against oxidative and frame-shift mutation when
present extracellularly, indicating a clear role for BPs in neutralis-
ing mutagens before entering cells. Furthermore, it should be
noted that BR causes apoptosis in cancer cells in vitro (Keshavan
et al., 2004), providing an additional mechanism for chemopreven-
tion. These data further emphasise the importance of therapeuti-
cally elevating BR concentrations for the prevention of
cardiovascular disease and cancer (McCarty, 2007). Reports to indi-
cate that BV and BRDT are readily absorbed across cultured entero-
cytes (Bulmer et al., 2008a) support this theory. These data conﬁrm
that potential anti-mutagenic BP effects in vivo could be induced
by increasing concentrations in the gut lumen (Bulmer et al.,
2011) where food-borne mutagens are found, or by increasing
blood BP content in vivo to impart protection from DNA damage
(Wallner et al., 2012). Although the results of these in vitro exper-
iments cannot be directly extrapolated to in vivo settings, the re-
sults suggest BPs in the extracellular milieu (e.g., in the gut
lumen/blood) could play a key role in cellular protection, by inter-
cepting mutagens before they arrive at their site of action (e.g.,
DNA).Conﬂict of interest statement
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